



a sanofi company

Mast Cell Innovation Awards

2026 Research Funding Opportunity

The Mast Cell Innovation Awards (iAwards) are a Blueprint Medicines funding initiative designed to support innovative translational and applied research in systemic mastocytosis, mast cell activation syndrome, and related mast cell disorders.

The iAwards seek to foster high-value research that advances scientific understanding, enhances patient identification and disease characterization, and generates meaningful evidence to inform clinical management and improve patient outcomes.

Submissions will undergo rigorous review based on scientific merit, feasibility, alignment with current research priorities, and available resources. Proposals that overlap or compete with our current and/or future studies will not be considered.

Important Dates

Call Opens for RFP – June 15, 2026
Submission Deadline – July 31, 2026

E-Mail Questions and Submissions to grants@blueprintmedicines.com

Eligibility is currently limited to U.S.-based academic investigators and institutions with a demonstrated history of successfully completing prior research engagements with Blueprint Medicines.

EXPECTATIONS

Submission must include:

- A full protocol, including the nature and scope of the support requested;
- A curriculum vitae (CV) or resume that documents previous clinical research experience of the proposed investigator(s) and other key research staff;
- Complete Blueprint project budget template, including itemization of costs, services and institutional fees; and
- Proposed study timelines and milestones, including a description of anticipated post-study activities and publications.

A blind evaluation will be completed for all submitted protocols. Protocols will be evaluated based on six (6) criteria.

- Alignment with area of interest
- Scientific merit
- Contribution to the understanding of our products and/or relevant disease area
- Feasibility
- Research completion timelines
- Budget

Milestone-based funding will be provided over 12 months. Non-interventional clinical or human-data studies may receive up to an additional 12 months if needed for start-up, data access, recruitment, or other design-related considerations.

SCOPE

To be considered for Blueprint Medicines support, projects MUST align with and adhere to the following research areas:

- Translational science tied to disease biology
- Biomarker, assay, and diagnostic development
- Natural history and phenotyping research
- Real-world evidence supporting disease understanding, patient identification, or care pathways

NEXT STEPS

To apply:

Email completed submission to grants@blueprintmedicines.com.

Approval notification:

All submissions will be reviewed by the Scientific Review Committee, and those selected will be notified on or around August 30, 2026.

Additional information:

If interested in speaking with a Medical Affairs Representative, please email medinfo@blueprintmedicines.com.

At the conclusion of the study, a Final Study Report and at least one draft external scientific output must be produced, such as a congress abstract, manuscript, or other publication-ready scientific summary.

Frequently Asked Questions – Mast Cell Innovation Awards (iAwards) **2026 Research Funding Opportunity**

When is the application deadline?

Applications will be accepted beginning 15 June 2026 and the submission deadline is 31 July 2026.

When will selections be awarded?

Blueprint Medicines will endeavor to forward decisions no later than 30 August 2026.

Is there a cap on the cost per submission?

There is no formal budget cap; however, budget will be an important factor in the review of each submission. Requested costs must be appropriate to the proposed scope of work, aligned with current Fair Market Value (FMV), and supported by a clear scientific and operational rationale. While proposals will be reviewed holistically, studies in the approximate range of \$150,000 are expected to align most closely with current program planning. Requests substantially above that level may be considered only with limited cases where the scientific, clinical, and strategic value is especially compelling. Capital expenses, office supplies, and similar non-research costs should not be included and will not be considered for support.

How do I apply?

To apply, send completed proposal to grants@blueprintmedicines.com by the designated deadline.

What makes up a complete submission?

A complete submission MUST INCLUDE the following:

- A full protocol, including the nature and scope of the support requested;
- A curriculum vitae (CV) or resume that documents previous clinical research experience of the proposed investigator(s) and other key research staff;
- Detailed project budget, including itemization of costs, services and institutional overhead;
- Proposed IST timelines and milestones, including a description of anticipated post-IST activities and publications.

What are the necessary parts of a complete protocol?

The protocol or research plan should be sufficiently developed to support scientific review by Blueprint Medicines and, if selected, to proceed through institutional review and approval processes with minimal refinement. At a minimum, submissions should include the following:

- *General Information:* study title, Principal Investigator name, institution, and contact details
- *Scientific Background & Rationale:* disease or investigational focus, summary of relevant non-clinical/clinical findings, potential risks and benefits
- *Research Objectives:* research question and study purpose
- *Study Design & Methodology:* overall study design, target population or data source, key procedures/assessments, and planned research activities (including study schema or Schule, if applicable)
- *Endpoints & Analysis:* primary and secondary endpoints, planned outputs, and data/statistical analysis plan
- *Timeline & Milestones:* key milestones (e.g., study start-up, enrollment, completion, final reporting)
- *Budget & Funding Rationale:* summary budget with justification
- *Dissemination Plan:* anticipated scientific outputs (e.g., publications, presentations)

Additional requirements for clinical or human-data research, as applicable:

- Eligibility criteria or subject selection approach
- Informed consent process
- Ethics/IRB considerations
- Safety monitoring approach
- Data handling, storage, and access plan

What if I have an idea that doesn't align with this RFP's scope of research areas?

Blueprint Medicines will continue to accept and evaluate proposals outside of the designated scope through the Investigator-Sponsored Research Support Program. Please note, there is a different submission process: requests for IST support (IST Concept) must be submitted via the [web-based portal](#). The IST Concept will be reviewed by Blueprint Medicines' Scientific Review Committee (SRC). If the SRC approves the IST Concept, the investigator will be invited to submit a more detailed proposal. We recommend you visit our [Investigator Sponsored Research Program](#) page for more information.

Can one institution submit multiple proposals?

Yes, provided each is submitted as a SEPERATE, INDEPENDENT submission and each must be complete and encompass all necessary documents listed above.

Can investigators collaborate on a single submission?

Yes. Multi-institution submissions are permitted; however, any additional site-related costs must be included within the overall proposed budget, and the timeline should account for required multi-site activities such as site selection, contracting, and subcontracting. Overall cost and timeline feasibility will be considered as part of the proposal review.

I've never worked with Blueprint Medicines before, am I eligible?

No. Eligibility is currently limited to U.S.-based academic investigators and institutions with a demonstrated history of successfully completing prior research engagements with Blueprint Medicines. If you have not worked with us before, we recommend you visit our [Investigator Sponsored Research Program](#) page for more information on how to submit a standard request.

Will there be requests for information (RFI) to clarify components of the submitted proposal?

All submissions will be checked for completeness prior to review. If clarification is needed, the grant manager may reach out to the applicant. Blueprint Medicines may also issue a request for information during review, as needed; however, applicants should ensure that proposals are as complete and thorough as possible at the time of submission.

Contact us at grants@blueprintmedicines.com for any additional questions regarding application process or the RFP program.